RESUMO
AIM: The aim of the study was to study the effectiveness of the complex use of bacterial therapeutic vaccine Immunovac-VP4 and allergen-specific immune therapy (ASIT) in pollinosis in children and adults. MATERIALS AND METHODS: Bacterial therapeutic vaccine Immunovac-VP4 was used annually, nasal and oral administration in patients before the course of ASIT standardized aqueous-salt solutions of allergens. RESULTS: The therapeutic application of bacterial vaccines, Immunoac-ÐÐ4 before the course ASIT has helped to reduce the frequency of acute respiratory infections in 8,5 times in comparison with the control group. Clinical efficacy of complex treatment according to the results of the survey of patients in 7 years after the start of therapy was 90%. There was a significant decrease In IgG4 to causally significant allergens, General immnunoglobulin E (IgE) and a tendency to decrease IgE. CONCLUSION: The use of bacterial therapeutic vaccine Immunovac-VP4, which is a natural ligand of toll-like receptors in combination with ASIT, seems to be an effective and promising direction in the treatment of allergic diseases.
Assuntos
Vacinas Bacterianas , Dessensibilização Imunológica , Rinite Alérgica Sazonal , Adulto , Alérgenos , Vacinas Bacterianas/uso terapêutico , Criança , Humanos , Rinite Alérgica Sazonal/imunologia , Rinite Alérgica Sazonal/terapia , Resultado do TratamentoRESUMO
AIM: Assessment of clinical and immunological effects of use of bacterial therapeutic polycomponent vaccine Immunovac-VP4 for allergen-specific immunotherapy (ASIT) of hay fever. MATERIALS AND METHODS: Five doses of Immunovac-VP4 vaccine consisted of antigens of opportunistic bacteria was used and administered by nasal-oral route. ASIT was performed with standard water-saline solution of allergens according to defined schedule. Sixty-nine patients with season rhinoconjunctivitis, asthma and their combinations were included in the study and divided to two groups. Skin scarification test was performed, total level of serum IgE, IgG4 and IgE to pollen allergens were measured by ELISA. Also, questionnaire was sent to patients yearly. RESULTS: Administration of bacterial therapeutic vaccine Immunovac-VP4 before start of ASIT resulted in marked clinical and immunological effect. In group of patients receiving combination therapy compared to control group, 8.5 times lower incidence of acute respiratory infections was registered. According to results of analysis of patients' questionnaires after 7 years, effectiveness of therapy was 90% that points to achievement of prolonged remission after completion of ASIT course. CONCLUSION: Utilization of natural ligands of Toll-like receptors is a perspective direction for development of new immunotherapeutic strategies for treatment of allergic diseases.